Compile Data Set for Download or QSAR
maximum 50k data
Found 90 with Last Name = 'aono' and Initial = 'h'
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527568(US11186588, Example 26)
Affinity DataIC50:  12.3nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527554(US11186588, Example 9)
Affinity DataIC50:  17.6nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Santen Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50132151(CHEMBL101683 | N-(4-Chloro-phenyl)-2-[(pyridin-4-y...)
Affinity DataIC50:  20nMAssay Description:Inhibition of KDR by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Santen Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM9503(2-[(pyridin-4-ylmethyl)amino]-N-[3-(trifluoromethy...)
Affinity DataIC50:  23nMAssay Description:Inhibition of KDR by ELISAMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Santen Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50377602(CHEMBL256556)
Affinity DataIC50:  26nMAssay Description:Inhibition of KDR by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527550(US11186588, Example 5)
Affinity DataIC50:  27.5nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527563(US11186588, Example 21 | US11186588, Example 22)
Affinity DataIC50:  30.3nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527557(US11186588, Example 12)
Affinity DataIC50:  32.1nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527563(US11186588, Example 21 | US11186588, Example 22)
Affinity DataIC50:  33.6nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527616(US11186588, Example 92)
Affinity DataIC50:  34.2nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Santen Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM4851((4-chlorophenyl)-[4-(4-pyridylmethyl)phthalazin-1-...)
Affinity DataIC50:  37nMAssay Description:Inhibition of KDR by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Santen Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50377603(CHEMBL402002)
Affinity DataIC50:  46nMAssay Description:Inhibition of KDR by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527608(US11186588, Example 81)
Affinity DataIC50:  47.2nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527567(US11186588, Example 25)
Affinity DataIC50:  50.3nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527549(US11186588, Example 3)
Affinity DataIC50:  51.9nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527560(US11186588, Example 16)
Affinity DataIC50:  77.5nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527551(US11186588, Example 6)
Affinity DataIC50:  86.4nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527572(US11186588, Example 33)
Affinity DataIC50:  87.2nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527610(US11186588, Example 83 | US11186588, Example 86)
Affinity DataIC50:  95.3nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527617(N-(4-(2,3,9-trimethyl-6H-thieno[2,3-e][1,2,4]triaz...)
Affinity DataIC50:  96nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527553(US11186588, Example 8)
Affinity DataIC50:  104nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527575(US11186588, Example 38)
Affinity DataIC50:  106nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527609(US11186588, Example 82)
Affinity DataIC50:  135nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527561(US11186588, Example 18)
Affinity DataIC50:  144nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527571(US11186588, Example 31)
Affinity DataIC50:  150nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527565(US11186588, Example 23)
Affinity DataIC50:  158nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527555(US11186588, Example 10)
Affinity DataIC50:  192nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527585(US11186588, Example 49)
Affinity DataIC50:  197nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Santen Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50377606(CHEMBL427725)
Affinity DataIC50:  200nMAssay Description:Inhibition of KDR by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527558(US11186588, Example 13)
Affinity DataIC50:  233nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527601(US11186588, Example 73)
Affinity DataIC50:  246nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527587(US11186588, Example 51)
Affinity DataIC50:  265nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527570(US11186588, Example 29)
Affinity DataIC50:  265nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527559(US11186588, Example 14)
Affinity DataIC50:  276nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527618(US11186588, Example 103 | US11186588, Example 99)
Affinity DataIC50:  289nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase ABL1(Homo sapiens (Human))
Santen Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50247766((E)-N-(4-(Morpholin-4-yl)phenyl)-3-(5-((Z)-3-oxo-3...)
Affinity DataIC50:  290nMAssay Description:Inhibition of ABL (unknown origin) expressed in baculovirus system by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527556(US11186588, Example 11)
Affinity DataIC50:  291nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527584(US11186588, Example 48)
Affinity DataIC50:  297nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527615(Synthesis of | US11186588, Example 90)
Affinity DataIC50:  298nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Santen Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50338503(4-(pyridin-4-ylmethylthio)-N-(3-(trifluoromethyl)p...)
Affinity DataIC50:  309nMAssay Description:Inhibition of KDR assessed as phosphorylation level of substrate by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527586(US11186588, Example 50)
Affinity DataIC50:  355nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527595(US11186588, Example 61)
Affinity DataIC50:  377nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527574(US11186588, Example 36)
Affinity DataIC50:  401nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527581(US11186588, Example 45)
Affinity DataIC50:  429nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527583(US11186588, Example 47)
Affinity DataIC50:  554nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527614(US11186588, Example 89)
Affinity DataIC50:  556nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527592(US11186588, Example 57)
Affinity DataIC50:  558nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527573(US11186588, Example 34)
Affinity DataIC50:  612nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527576(US11186588, Example 39)
Affinity DataIC50:  620nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527613(US11186588, Example 88)
Affinity DataIC50:  631nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 90 total ) | Next | Last >>
Jump to: